ZM 447439

製品コードS1103

ZM 447439化学構造

分子量(MW):513.59

ZM 447439は一種の選択性的で、ATP競争性的なオーロラAとオーロラ Bの阻害剤で、IC50値が110 nMと130 nMです。ZM 447439は、オーロラA/オーロラ Bに作用する選択性はMEK1、 SrcとLckに作用する選択性より8倍がそれぞれ高くなりますが、CDK1/2/4、Plk1とChk1等に作用する効果が殆どありません。

サイズ 価格(税別) 在庫  
JPY 16268.00 あり
JPY 11620.00 あり
JPY 18260.00 あり
JPY 44820.00 あり
JPY 78020.00 あり

カスタマーフィードバック(3)

  • p31comet depletion delays MCC disassembly even with the proteasome inhibited. (A) FACS analysis of HeLa Tet-on cells transfected with control or p31comet siRNA and then treated with Taxol followed by Aurora B inhibition with ZM447439. The percentage of mitotic cells (cells that have 4N DNA content and are MPM2 positive) is shown for each sample.

    Mol Biol Cell 2011 22, 4227-35. ZM 447439 purchased from Selleck.

    HeLa cells were treated with Nocodazole (100ng/ml) (Lanes 2-4) or Taxol (1µM) (Lanes 6-8) or DMSO (lanes 1, 5) for 16h. The indicated inhibitors were added for 2h (1 µM) before harvesting the cells. The p-Aurora-A (T288), B (T232), C (T198) antibody was from Cell Signaling (#2914). MK5108 is an Aurora-A inhibitor. VX680 inhibits all three Aurora kinases. ZM447439 inhibits both Aurora-B and -C kinases, but not Aurora-A kinase.

    Dr. Yuanhong Chen of University of Nebraska. ZM 447439 purchased from Selleck.

  • Western blot analysis of Histone and Aurora kinase. 0-10μM ZM447439 was added.

    Dr. Zhang of Tianjin Medical University. ZM 447439 purchased from Selleck.

製品安全説明書

Aurora Kinase阻害剤の選択性比較

生物活性

製品説明 ZM 447439は一種の選択性的で、ATP競争性的なオーロラAとオーロラ Bの阻害剤で、IC50値が110 nMと130 nMです。ZM 447439は、オーロラA/オーロラ Bに作用する選択性はMEK1、 SrcとLckに作用する選択性より8倍がそれぞれ高くなりますが、CDK1/2/4、Plk1とChk1等に作用する効果が殆どありません。
特性 An Aurora selective ATP-competitive inhibitor.
ターゲット
Aurora A [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
LCK [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
MEK1 [1]
(Cell-free assay)
110 nM 130 nM 880 nM 1.03 μM 1.79 μM
体外試験

In vitro, ZM-447439 selectively inhibits recombinant human Aurora A and B with IC50 values of 110 and 130 nM, respectively, while other protein kinases of diverse structural types including the mitotic kinases CDK1 and PLK1 are inhibited with IC50 values >10 μM. [1] Aurora kinase inhibitor, ZM-447439 time- and dose-dependently inhibits the growth of all three cell lines with IC50 values of 3 μM (BON), 0.9 μM (QGP-1) and 3 μM (MIP-101) after 72 hours of continuous exposure. In addition, ZM-447439 potently induces cell apoptosis by promoting DNA fragmentation and caspase 3 and 7 activation, and arrests GEP-NET cells in the G0 /G1and G2/M phase of the cell cycle. [2] In mouse embryo, inhibition of Aurora kinase activity by ZM-447439 results in abnormalities during mitosis by regulating the phosphorylation of histone H3 serine 10 (H3S10Ph) from G2 to metaphase with different perturbations in each embryonic cycle. [3] A recent study shows that ZM-447439 exhibits growth inhibitory and proapoptotic effect on cervical cancer SiHa cells, and enhances the chemosensitivity to cisplatin. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell NWDZd2lxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnHSTY5pcWKrdHnvckBw\iCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zOE[3PEDPxE1? M4PReHNCVkeHUh?=
MCF7 cell NIPrOpVRem:uaX\ldoF1cW:wIHHzd4F6 NYrt[HJVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBOS0Z5IHPlcIwhdGmwZTygTWM2OD1yLkG5PEDPxE1? M3TQOFE3OzN5MUKy
human P12-ICHIKAWA cell NIjFPHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIn2e4FKdmirYnn0bY9vKG:oIHj1cYFvKFBzMj3JR2hKU0GZQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlI1PDFizszN NUDGUoNOW0GQR1XS
human KARPAS-45 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2TmZmlvcGmkaYTpc44hd2ZiaIXtZY4hU0GUUFHTMVQ2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|OEGyPEDPxE1? M2jFRnNCVkeHUh?=
human ES3 cell Mn6yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUe0fJIzUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4OzJizszN MojHV2FPT0WU
human ES8 cell NF;OdYxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MonBTY5pcWKrdHnvckBw\iCqdX3hckBGWzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkS5PFA3KM7:TR?= Mnn5V2FPT0WU
human TE-11 cell M3HGTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYPJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTFzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61N|cxOyEQvF2= NWTadm9wW0GQR1XS
human RS4-11 cell M{LTTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXnlVZp5UW6qaXLpeIlwdiCxZjDoeY1idiCUU{StNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjV3NESg{txO M3;pZXNCVkeHUh?=
human MOLT-16 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2\NdWlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjB7NkGg{txO NXnuT4pCW0GQR1XS
human RKO cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHrCb2pKdmirYnn0bY9vKG:oIHj1cYFvKFKNTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|A3PTZizszN M1TNW3NCVkeHUh?=
human MV-4-11 cell MoW3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmTpTY5pcWKrdHnvckBw\iCqdX3hckBOXi12LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QTZ|IN88US=> M{LXR3NCVkeHUh?=
human SW954 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWrJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTV2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64N|Y{PSEQvF2= M1;lNHNCVkeHUh?=
human BE-13 cell NInlTppIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWDXbVZpUW6qaXLpeIlwdiCxZjDoeY1idiCERT2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDR2MUig{txO MUPTRW5ITVJ?
human MOLT-4 cell MnX0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlnZTY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg6QTd6IN88US=> M1L2VnNCVkeHUh?=
human NBsusSR cell NW\nUG5jT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXvnTmY{UW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57MUO4O{DPxE1? NV3Sb3o2W0GQR1XS
human H9 cell NY\WS5ZjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEjrXpdKdmirYnn0bY9vKG:oIHj1cYFvKEh7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65Nlk4QSEQvF2= MVXTRW5ITVJ?
human A172 cell MoPQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnjhTY5pcWKrdHnvckBw\iCqdX3hckBCOTd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65PFQyOSEQvF2= MkPjV2FPT0WU
human ES5 cell MmW4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXrJcohq[mm2aX;uJI9nKGi3bXHuJGVUPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMECyOFgh|ryP Ml3wV2FPT0WU
human SBC-1 cell NGnIepBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVzJcohq[mm2aX;uJI9nKGi3bXHuJHNDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6wN|kzQCEQvF2= NFfPdIhUSU6JRWK=
human NCI-H209 cell NUP3NHhtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkC5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yPjZyMjFOwG0> NYnNTVU4W0GQR1XS
human NKM-1 cell MnzkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXjiO2pEUW6qaXLpeIlwdiCxZjDoeY1idiCQS12tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTZ5OUig{txO MnXxV2FPT0WU
human NCI-H720 cell MoPLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{LtUWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3NlAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJyNkK3JO69VQ>? NH;OfHVUSU6JRWK=
human KE-37 cell NUnGZll{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFLleZRKdmirYnn0bY9vKG:oIHj1cYFvKEuHLUO3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOTN6ODFOwG0> MVzTRW5ITVJ?
human SW48 cell NVW0VZdMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlP5TY5pcWKrdHnvckBw\iCqdX3hckBUXzR6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6yN|E2PSEQvF2= MVXTRW5ITVJ?
human IST-SL1 cell NVPMZlRLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEXrS|FKdmirYnn0bY9vKG:oIHj1cYFvKEmVVD3TUFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjNzN{K3JO69VQ>? M2nKeXNCVkeHUh?=
human SK-NEP-1 cell M1ntcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml7NTY5pcWKrdHnvckBw\iCqdX3hckBUUy2QRWCtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzZ2OUig{txO NVXKV5dOW0GQR1XS
human NOMO-1 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2rySWlvcGmkaYTpc44hd2ZiaIXtZY4hVk:PTz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{Pjd{NTFOwG0> M1TwWHNCVkeHUh?=
human DOHH-2 cell NHzmeHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWG0bHlpUW6qaXLpeIlwdiCxZjDoeY1idiCGT1jIMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjRyMke2JO69VQ>? NXf4NYM6W0GQR1XS
human ABC-1 cell NX3a[21rT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH;MOIhKdmirYnn0bY9vKG:oIHj1cYFvKEGEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41ODN3MjFOwG0> NUjDZY5YW0GQR1XS
human Ramos-2G6-4C10 cell M2X5PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NELESG5KdmirYnn0bY9vKG:oIHj1cYFvKFKjbX;zMVJIPi12Q{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41ODZyNTFOwG0> MVjTRW5ITVJ?
human EM-2 cell M{G3V2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF\5PHpKdmirYnn0bY9vKG:oIHj1cYFvKEWPLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQyPzJzIN88US=> NX7sSmg4W0GQR1XS
human NB14 cell M1jYe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mkf6TY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT61OVYzOSEQvF2= NIrIU5lUSU6JRWK=
human MOLT-13 cell M{KxZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXLJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU3PzB4IN88US=> NVf0d417W0GQR1XS
human ECC10 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFPpXmVKdmirYnn0bY9vKG:oIHj1cYFvKEWFQ{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OzN3MzFOwG0> MnziV2FPT0WU
human LK-2 cell NV30R4I2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4XvOGlvcGmkaYTpc44hd2ZiaIXtZY4hVEtvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlQ2QTRizszN MonCV2FPT0WU
human CTB-1 cell NYD4RVRGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3n1cGlvcGmkaYTpc44hd2ZiaIXtZY4hS1SELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY4ODh{IN88US=> MmTXV2FPT0WU
human NCI-H1581 cell Ml\iS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEG1NINKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVU5OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNke1OUDPxE1? NH3qSJlUSU6JRWK=
human COLO-800 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MorGTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUiwNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzB|OEKg{txO NVTsd3lsW0GQR1XS
human NB7 cell NGOxWZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV\Jcohq[mm2aX;uJI9nKGi3bXHuJG5DPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwN{WyPVch|ryP NX;iXpRwW0GQR1XS
human LAMA-84 cell M3OybGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXnEdGlJUW6qaXLpeIlwdiCxZjDoeY1idiCOQV3BMVg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS55NUWyJO69VQ>? MW\TRW5ITVJ?
human HCT-116 cells NVize4plT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MknnTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45ODlyODFOwG0> MW\TRW5ITVJ?
SK-UT-1 cell M2T3XWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1z2dWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvVWStNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQDF3MzFOwG0> MWnTRW5ITVJ?
human H4 cell MknzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWjqR|RmUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPFE2PzhizszN M{PGSXNCVkeHUh?=
human CAL-51 cell NYP4[WlrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4DqNWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45Ozh2NTFOwG0> Mn3UV2FPT0WU
human LoVo cells Ml3FVJJwdGmoZYLheIlwdiCjc4PhfS=> NIC1cGw4OiCq MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyxVn:gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVD3iZZNm\CCZU2S4JJJm[WenboSgZZN{[XluIFnDOVA:OS57IN88US=> NHm1bIczPTJ5MESwNy=>
human HN cell MnjDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWn3bYhbUW6qaXLpeIlwdiCxZjDoeY1idiCKTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVI2OSEQvF2= NFjrcWhUSU6JRWK=
human L-363 cell NYDLdI5bT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmrITY5pcWKrdHnvckBw\iCqdX3hckBNNTN4MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVUyOiEQvF2= NELIOGNUSU6JRWK=
human NCI-H747 cell M1nPVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYLJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{S3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4xOzN3MzFOwG0> M2DzdHNCVkeHUh?=
human A498 cell NYPjXI84T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUnJcohq[mm2aX;uJI9nKGi3bXHuJGE1QThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkO2Olkh|ryP MYHTRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

In vitro kinase assays :

Recombinant Aurora A and B are expressed as NH2-terminal His6-tagged fusion proteins using a baculovirus expression system. Aurora A is purified by affinity chromatography using Ni-NTA agarose, and Aurora B is purified by ion exchange chromatography using CM Sepharose Fast Flow. 1 ng purified recombinant enzyme is added to a reaction cocktail containing 25 mM Tris-HCl, pH 7.5, 12.5 mM KCl, 2.5 mM NaF, 0.6 mM DTT, 6.25 mM MnCl2, 10 μM peptide substrate, 10 μM for Aurora A or 5 μM ATP for Aurora B, and 0.2 μCi γ-[33P]ATP (specific activity ≥2,500 Ci/mmol), and is then incubated at RT for 60 minutes. Reactions are stopped by addition of 20% phosphoric acid, and the products are captured on P30 nitrocellulose filters and assayed for incorporation of 33P with a BetaplateTM counter. No enzyme and no compound control values are used to determine the concentration of ZM447439, which gave 50% inhibition of enzyme activity. Further details are available on request from Nicholas Keen.
細胞試験: [2]
+ 展開
  • 細胞株: BON, QGP-1 and MIP-101 cells
  • 濃度: 0-5 μM
  • 反応時間: 72 hours
  • 実験の流れ: Cell number is evaluated by crystal violet staining. In brief, cells in 96-well plates are fixed with 1% glutaraldehyde. Then cells are stained with 0.1% crystal violet. The unbound dye is removed by washing with water. Bound crystal violet is solubilized with 0.2% Triton X-100. Light extinction which increases linearly with the cell number is analyzed at 570 nm using an ELISA reader.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 103 mg/mL (200.54 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 513.59
化学式

C29H31N5O4

CAS No. 331771-20-1
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Aurora Kinase信号経路図

Aurora Kinase Inhibitors with Unique Features

相関Aurora Kinase製品

Tags: ZM 447439を買う | ZM 447439 ic50 | ZM 447439供給者 | ZM 447439を購入する | ZM 447439費用 | ZM 447439生産者 | オーダーZM 447439 | ZM 447439化学構造 | ZM 447439分子量 | ZM 447439代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID